Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a multinational observational study, independent from pharmaceutical support and involving both academic and community treatment centers, long-term follow-up for chronic myelogenous leukemia (CML) patients who, after two years of imatinib therapy, were in complete cytogenetic remission was undertaken for a median of 5.8 years. Although side effects were common, only a very small percentage of patients discontinued the drug and the majority maintained their cytogenetic response. In fact, the incidence of second malignancies and overall survival were no different for the CML patients in this cohort than for the general population in Italy.

Outcomes for Patients on Long-term Imatinib Treatment for Chronic Myelogenous Leukemia